General Home Investors News

MedinCell has launched a COVID-19 research initiative based on its experience to formulate long-acting injectable Ivermectin

By MedincellApril 6, 2020March 15th, 2024No Comments

MedinCell has launched a COVID-19 research initiative based on its experience to formulate long-acting injectable Ivermectin

April 6, 2020

Previous PostInvitation to a webcast: adapting and acting in response to the Covid-19 crisis
Next PostMedinCell receives $ 6.4 million grant from Unitaid to fight Malaria

Better medicine for all

Website by ScreenUp